HK1075422A1 - Use of il-18 inhibitors in the manufacture of medicaments - Google Patents

Use of il-18 inhibitors in the manufacture of medicaments

Info

Publication number
HK1075422A1
HK1075422A1 HK05109693.6A HK05109693A HK1075422A1 HK 1075422 A1 HK1075422 A1 HK 1075422A1 HK 05109693 A HK05109693 A HK 05109693A HK 1075422 A1 HK1075422 A1 HK 1075422A1
Authority
HK
Hong Kong
Prior art keywords
medicaments
inhibitors
manufacture
inhibitor
prevention
Prior art date
Application number
HK05109693.6A
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Merck Serono Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa, Inst Nat Sante Rech Med filed Critical Merck Serono Sa
Publication of HK1075422A1 publication Critical patent/HK1075422A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK05109693.6A 2002-03-22 2005-11-01 Use of il-18 inhibitors in the manufacture of medicaments HK1075422A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22
PCT/EP2003/050061 WO2003080104A2 (en) 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (1)

Publication Number Publication Date
HK1075422A1 true HK1075422A1 (en) 2005-12-16

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109693.6A HK1075422A1 (en) 2002-03-22 2005-11-01 Use of il-18 inhibitors in the manufacture of medicaments

Country Status (28)

Country Link
US (2) US9592267B2 (ru)
EP (1) EP1487541B1 (ru)
JP (1) JP4885424B2 (ru)
KR (1) KR20050004809A (ru)
CN (1) CN100540058C (ru)
AR (1) AR039103A1 (ru)
AT (1) ATE414556T1 (ru)
AU (1) AU2003219162B2 (ru)
BR (1) BRPI0308663B8 (ru)
CA (1) CA2478855C (ru)
CY (1) CY1108748T1 (ru)
DE (1) DE60324777D1 (ru)
DK (1) DK1487541T3 (ru)
EA (1) EA008495B1 (ru)
ES (1) ES2314191T3 (ru)
HK (1) HK1075422A1 (ru)
HR (1) HRP20040758B1 (ru)
IL (2) IL164211A0 (ru)
ME (1) ME00548B (ru)
MX (1) MXPA04009135A (ru)
NO (1) NO336226B1 (ru)
PL (1) PL207303B1 (ru)
PT (1) PT1487541E (ru)
RS (1) RS51755B (ru)
SI (1) SI1487541T1 (ru)
UA (1) UA80275C2 (ru)
WO (1) WO2003080104A2 (ru)
ZA (1) ZA200407022B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
TWI335336B (ru) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
KR20050004809A (ko) 2002-03-22 2005-01-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 말초 맥관 질환 치료 및/또는 예방에 사용되는 ｉｌ-18저해제
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
ES2429443T3 (es) * 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
DK1891088T3 (da) 2005-06-10 2012-01-30 Ares Trading Sa Fremgangsmåde til rensning af et IL-18-bindende protein
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
JP5844258B2 (ja) 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーＢｉｏｍｅｔ Ｂｉｏｌｏｇｉｃｓ， Ｌｌｃ インターロイキン−１受容体アンタゴニストの生産のための植込み型装置
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
PT2658551T (pt) 2010-12-29 2020-07-24 Strategic Science & Tech Llc Tratamento da disfunção erétil e outras indicações
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
MX2017010919A (es) * 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
EP1101772B1 (en) * 1999-11-16 2009-01-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
RS50926B (sr) * 2000-05-05 2010-08-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
KR20050004809A (ko) 2002-03-22 2005-01-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 말초 맥관 질환 치료 및/또는 예방에 사용되는 ｉｌ-18저해제

Also Published As

Publication number Publication date
CA2478855C (en) 2013-12-17
SI1487541T1 (sl) 2009-02-28
ZA200407022B (en) 2006-06-28
EP1487541B1 (en) 2008-11-19
US20060233799A1 (en) 2006-10-19
CN1655845A (zh) 2005-08-17
WO2003080104A2 (en) 2003-10-02
JP2005520852A (ja) 2005-07-14
IL164211A (en) 2011-07-31
BRPI0308663B8 (pt) 2021-05-25
MXPA04009135A (es) 2004-12-07
CY1108748T1 (el) 2014-04-09
DE60324777D1 (de) 2009-01-02
US9592267B2 (en) 2017-03-14
HRP20040758B1 (hr) 2012-10-31
RS81504A (en) 2006-12-15
KR20050004809A (ko) 2005-01-12
NO20044459L (no) 2004-10-20
DK1487541T3 (da) 2009-01-19
RS51755B (en) 2011-12-31
EA008495B1 (ru) 2007-06-29
CA2478855A1 (en) 2003-10-02
AU2003219162A1 (en) 2003-10-08
HRP20040758A2 (en) 2005-02-28
AU2003219162B2 (en) 2008-01-03
ME00548B (me) 2011-10-10
EP1487541A2 (en) 2004-12-22
PT1487541E (pt) 2008-12-10
JP4885424B2 (ja) 2012-02-29
NO336226B1 (no) 2015-06-22
US9566313B2 (en) 2017-02-14
UA80275C2 (en) 2007-09-10
IL164211A0 (en) 2005-12-18
US20100291028A1 (en) 2010-11-18
ATE414556T1 (de) 2008-12-15
BR0308663A (pt) 2005-01-25
ES2314191T3 (es) 2009-03-16
PL207303B1 (pl) 2010-11-30
WO2003080104A3 (en) 2004-03-04
BRPI0308663B1 (pt) 2019-07-16
PL372398A1 (en) 2005-07-25
EA200401240A1 (ru) 2005-02-24
AR039103A1 (es) 2005-02-09
CN100540058C (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
HK1075422A1 (en) Use of il-18 inhibitors in the manufacture of medicaments
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MY127290A (en) New use of flibanserin
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
GB0020504D0 (en) Therapeutic method
HK1062810A1 (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2004037233A3 (en) Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
MXPA04001230A (es) Uso de inhibidores de il-18 en desordenes de hipersensibilidad.
TNSN05154A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
EP1551456A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
IL164092A0 (en) The use of devazepide as analgesic agent
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
GEP20043317B (en) Ointment for Treatment of Purulent Diseases, Festering Wounds and Burns
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
PL1838392T3 (pl) Leki zawierające selen na śródbłonkowe choroby układu naczyniowego

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230312